SCA Pharma Expands Operations in Little Rock, Arkansas
07/22/2020
SCA will be investing more than $10 million and will create the opportunity to double its current Little Rock workforce of 180 people. Additionally, the investment will allow SCA Pharma to renovate an existing 42,000-square-foot facility at the Clinton National Airport and construct an additional 20,000-square-foot facility adjacent to the existing facility.
In addition, SCA announced last week that it also plans a 40 percent expansion of its facility in Windsor, Connecticut. The expansion of both locations will also create the need for technical and highly skilled jobs for both areas.
“We are very pleased that as we continue our geographical expansions in both Arkansas and Connecticut, we can partner with the Arkansas Economic Development Commission (AEDC) and the Little Rock Municipal Airport Commission to solidify and expand the operations of our legacy operations,” said Milton Boyer, CEO of SCA Pharma. “Little Rock has been the foundation that has allowed for our other expansion projects, and this project will bolster that foundation for years to come.”
“Arkansas is committed to nurturing its homegrown companies from seed stage upward,” Governor Asa Hutchinson said. “We are proud to see the success that SCA Pharma is experiencing and look forward to the products and services being developed here in central Arkansas that will positively impact the lives of people around the country.”
“As a national leader in compounded pharmaceutical manufacturing, SCA Pharma is a great fit for this area of the state,” Arkansas Department of Commerce Secretary and Executive Director of the AEDC Mike Preston said. “The company’s decision to expand in Arkansas speaks volumes about our state’s business climate and our workforce.”
“Even in these trying and turbulent times of a global pandemic and its uncertainty, Little Rock is continuing to see companies invest and create new jobs for our citizens,” said Mayor Frank Scott Jr. “We are thrilled and grateful SCA Pharma is joining Little Rock’s momentum and creating high-paying jobs that will have a lasting impact on our economy.”
“Founded in Little Rock just 10 years ago, we are pleased SCA Pharma will be expanding where they were founded,” Little Rock Regional Chamber Chair Ronnie Dedman said. “Their expansion proves that companies are finding the right talent to succeed in Little Rock.”
SCA, founded in Little Rock in 2010, said it has experienced significant growth over the past five years and has emerged as a leading manufacturer of compounded pharmaceuticals. Creating an additional clean room capacity will provide another avenue to increase supply.
Company officials said it is a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services to hospital pharmacies throughout the U.S. Choosing to outsource products with SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns.
Project Announcements
Eos Energy Enterprises Expands Allegheny County, Pennsylvania, Operations
11/01/2025
Ahold Delhaize USA Plans Burlington, North Carolina, Distribution Operations
11/01/2025
Ulbrich Specialty Wire Products Expands Westminster, South Carolina, Production Operation
11/01/2025
Alcoa Expands Massena, New York, Operations
11/01/2025
SmartWiz Expands Birmingham, Alabama, Headquarters Operations
11/01/2025
Dutch-Based Maars North America Plans Mount Pleasant, South Carolina, Production Operations
11/01/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025